• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过计算机辅助图像分析评估人前列腺癌组织芯片中白细胞介素-6、白细胞介素-10和热休克蛋白90的表达。

IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.

作者信息

Cardillo Maria Rosaria, Ippoliti Flora

机构信息

Department of Experimental Medicine and Pathology, Section of Pathologic Anatomy, Service of Uropathology, University "La Sapienza", Policlinico Umberto I, 324 Viale Regina Elena, 00161 Rome, Italy.

出版信息

Anticancer Res. 2006 Sep-Oct;26(5A):3409-16.

PMID:17094460
Abstract

The interleukins (IL)-6 and -10 and heat shock proteins (HSP) have an important role in the host-tumor interaction and in tumor bulk. HSP-90 may have a regulatory role in cytokine biosynthesis and prognostic value in some tumors. To define the role of IL-6, IL-10 and HSP-90 in prostate cancer progression the immunohistochemical expressions of these proteins were analyzed in 168 prostatic carcinomas. IL-6, IL-10 and HSP-90 immunoreactivity was higher in prostatic carcinoma (CaP) and intra-epithelial prostatic neoplasia (PIN) than in normal prostatic tissue (NAP) adjacent to neoplasia. In the epithelium, IL-6, IL-10 and HSP-90 expressions increased from NAP to PIN to CaP. In the stroma, IL-6 and IL-10 expressions decreased significantly from NAP to PIN to CaP (p < 0.01 by Chi-square test), while HSP-90 expression increased. In the epithelium of PIN and CaP, IL-6 immunoreactivity was significantly lower than IL-10 and HSP-90. In neoplastic acini HSP-90 levels were significantly higher than those of IL-6 and IL-10 (p < 0.01 by Chi-square test). In the stroma of NAP and PIN, but not of CaP, HSP-90 immunoreactivity was significantly lower than that of IL-6 and IL-10 (p < 0.01). Our results indicate that the IL-6 and IL-10 cytokine balance differs in pathological and normal prostate, thus suggesting that certain cytokines are specific to the neoplastic prostate. Changes in the expressions of IL-6, IL-10 and HSP-90 in human prostate carcinoma samples could be used as a prognostic marker of disease progression.

摘要

白细胞介素(IL)-6、-10和热休克蛋白(HSP)在宿主与肿瘤的相互作用以及肿瘤体积方面发挥着重要作用。HSP-90可能在细胞因子生物合成中具有调节作用,并且在某些肿瘤中具有预后价值。为了明确IL-6、IL-10和HSP-90在前列腺癌进展中的作用,对168例前列腺癌组织中这些蛋白的免疫组化表达进行了分析。前列腺癌(CaP)和前列腺上皮内瘤变(PIN)中IL-6、IL-10和HSP-90的免疫反应性高于肿瘤旁正常前列腺组织(NAP)。在前列腺上皮中,IL-6、IL-10和HSP-90的表达从NAP到PIN再到CaP逐渐增加。在前列腺基质中,IL-6和IL-10的表达从NAP到PIN再到CaP显著降低(卡方检验,p<0.01),而HSP-90的表达增加。在PIN和CaP的上皮中,IL-6的免疫反应性显著低于IL-10和HSP-90。在肿瘤腺泡中,HSP-90水平显著高于IL-6和IL-10(卡方检验,p<0.01)。在NAP和PIN的基质中,而非CaP的基质中,HSP-90的免疫反应性显著低于IL-6和IL-10(p<0.01)。我们的结果表明,IL-6和IL-10细胞因子平衡在病理状态和正常前列腺组织中存在差异,这表明某些细胞因子是前列腺肿瘤所特有的。人前列腺癌样本中IL-6、IL-10和HSP-90表达的变化可作为疾病进展的预后标志物。

相似文献

1
IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.通过计算机辅助图像分析评估人前列腺癌组织芯片中白细胞介素-6、白细胞介素-10和热休克蛋白90的表达。
Anticancer Res. 2006 Sep-Oct;26(5A):3409-16.
2
Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer.前列腺癌中金属蛋白酶的定量免疫组织化学和原位杂交分析
Anticancer Res. 2006 Mar-Apr;26(2A):973-82.
3
Heat shock protein expression independently predicts clinical outcome in prostate cancer.热休克蛋白表达可独立预测前列腺癌的临床结局。
Cancer Res. 2000 Dec 15;60(24):7099-105.
4
Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.微血管密度作为一种分子标志物,用于识别前列腺癌的高级别前列腺上皮内瘤变前体。
Exp Mol Pathol. 2004 Oct;77(2):153-9. doi: 10.1016/j.yexmp.2004.04.005.
5
Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.视网膜母细胞瘤和p53肿瘤抑制基因在前列腺上皮内瘤变中的免疫组化表达:与前列腺腺癌和良性前列腺的比较。
Mod Pathol. 1998 Mar;11(3):247-52.
6
Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.白细胞介素-6细胞因子家族及其受体在人良性、增生性和恶性前列腺组织中的免疫组织化学分析
J Pathol. 2004 Jan;202(1):41-9. doi: 10.1002/path.1476.
7
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.双重5α-还原酶抑制剂度他雄胺可诱导人体前列腺发生萎缩性变化并减小相对癌体积。
Urology. 2005 Jan;65(1):76-82. doi: 10.1016/j.urology.2004.08.042.
8
Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.胰岛素样生长因子(IGF)-I、IGF-II及I型胰岛素样生长因子受体(IGFR-I)在前列腺癌中的表达
Anticancer Res. 2003 Sep-Oct;23(5A):3825-35.
9
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.人类前列腺癌中的反应性基质:肌成纤维细胞表型的诱导和细胞外基质重塑。
Clin Cancer Res. 2002 Sep;8(9):2912-23.
10
Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.人前列腺癌和高级别前列腺上皮内瘤变中促红细胞生成素受体的上调
Prostate Cancer Prostatic Dis. 2008;11(2):143-7. doi: 10.1038/sj.pcan.4500995. Epub 2007 Jul 17.

引用本文的文献

1
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).克隆性造血与转移性去势抵抗性前列腺癌患者接受雄激素受体通路抑制剂治疗的临床结局(Alliance A031201)。
Clin Cancer Res. 2024 Nov 1;30(21):4910-4919. doi: 10.1158/1078-0432.CCR-24-0803.
2
Impacts of Interleukin-10 Promoter Genotypes on Prostate Cancer.白细胞介素-10启动子基因型对前列腺癌的影响。
Life (Basel). 2024 Aug 20;14(8):1035. doi: 10.3390/life14081035.
3
A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer.
一种基于布尔运算的机器学习框架可识别前列腺癌中HSP90靶向治疗反应的预测性生物标志物。
Front Mol Biosci. 2023 Jan 19;10:1094321. doi: 10.3389/fmolb.2023.1094321. eCollection 2023.
4
The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.前列腺癌中的肿瘤固有免疫微环境:可溶性因子和细胞效应器概述
Explor Target Antitumor Ther. 2022;3(5):694-718. doi: 10.37349/etat.2022.00108. Epub 2022 Oct 31.
5
High-throughput microfluidic 3D biomimetic model enabling quantitative description of the human breast tumor microenvironment.高通量微流控 3D 仿生模型可定量描述人类乳腺肿瘤微环境。
Acta Biomater. 2021 Sep 15;132:473-488. doi: 10.1016/j.actbio.2021.06.025. Epub 2021 Jun 18.
6
Heat shock protein 90α in thymic epithelial tumors and non-thymomatous myasthenia gravis.热休克蛋白 90α 在胸腺瘤和非胸腺瘤重症肌无力中的表达。
Oncoimmunology. 2020 May 13;9(1):1756130. doi: 10.1080/2162402X.2020.1756130.
7
Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.通过对患者来源的前列腺肿瘤外植体的蛋白质组谱分析鉴定 HSP90 抑制剂的新型反应和预测性生物标志物。
Mol Cell Proteomics. 2018 Aug;17(8):1470-1486. doi: 10.1074/mcp.RA118.000633. Epub 2018 Apr 9.
8
Delivery of HSP90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload.采用高载药水溶性聚合物缀合物递送 HSP90 抑制剂。
Pharm Res. 2017 Dec;34(12):2735-2748. doi: 10.1007/s11095-017-2249-5. Epub 2017 Sep 14.
9
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.一项关于ganetespib(一种热休克蛋白90(Hsp90)抑制剂)用于多西他赛预处理的转移性去势抵抗性前列腺癌(CRPC)患者的II期试验——一项前列腺癌临床试验联盟(PCCTC)研究。
Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18.
10
Steroid Receptor-Associated Immunophilins: A Gateway to Steroid Signalling.类固醇受体相关亲免素:通往类固醇信号传导的门户
Clin Biochem Rev. 2015 May;36(2):31-52.